SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-20-005465
Filing Date
2020-03-05
Accepted
2020-03-05 08:16:35
Documents
9
Period of Report
2020-03-05

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea119269-6k_enlivextherape.htm 6-K 27501
2 FORM OF SECURITIES PURCHASE AGREEMENT ea119269ex1-1_enlivex.htm EX-1.1 226830
3 FORM OF INVESTOR WARRANT ea119269ex4-1_enlivex.htm EX-4.1 110889
4 FORM OF PLACEMENT AGENT WARRANT ea119269ex4-2_enlivex.htm EX-4.2 117081
5 OPINION OF YIGAL ARNON & CO ea119269ex5-1_enlivex.htm EX-5.1 13033
6 OPINION OF GREENBERG TRAURIG, LLP ea119269ex5-2_enlivex.htm EX-5.2 25456
7 PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON MARCH 3, 2020 ea119269ex99-1_enlivex.htm EX-99.1 11260
8 PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON MARCH 5, 2020 WITH RESPECT ea119269ex99-2_enlivex.htm EX-99.2 11769
9 GRAPHIC image_002.jpg GRAPHIC 9976
  Complete submission text file 0001213900-20-005465.txt   558941
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 20689680
SIC: 2834 Pharmaceutical Preparations